Vorhofflimmern als Endpunkt bei Studien zur arteriellen Hypertonie

Literatur

• 1 Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension.  Am Heart J. 2000;  139 814-819
• 2 Dahlöf B, Devereux R B, Kjeldsen S E, Julius S, Beevers G, de Faire U, Fyrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm L H, Nieminen M S, Omvik P, Oparil S, Wedel H. for the LIFE study group . Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 3 Dunn F G, Chandraratna P, de Carvalho J GR, Basta L L, Fröhlich E D. Pathophysiologic assessment of hypertensive heart disease with echocardiography.  Am J Cardiol. 1977;  39 789-795
• 4 Fuster V, Rydén L E, Asinger R W, Cannom D S, Crijns H J, Frye R L, Halperin J L, Kay G N, Klein W W, Lévy S, McNamara R L, Prystowsky E N, Wann L S, Wyse G D. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences.  Eur Heart J. 2001;  22 1852-1923
• 5 Gerdts E, Oikarinen L, Palmieri V, Otterstad J E, Wachtell K, Boman K, Dahlöf B, Devereux R B. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy. The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study.  Hypertension. 2002;  39 739-743
• 6 Goette A, Lendeckel U, Klein H U. Signal transduction systems and atrial fibrillation.  Cardiovasc Research. 2002;  54 247-258
• 7 Gottdiener J S, Reda D J, Williams D W, Materson B J, Cushman W, Anderson R J. for the VA Cooperative Study Group on Antihypertensive Agents . Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension. Comparison of six antihypertensive agents.  Circulation. 1998;  98 140-148
• 8 Hannson L, Lindholm L H, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P O, Hedner T, de Faire U. for the STOP-Hypertension-2 study group . Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.  Lancet. 1999;  354 1751-1756
• 9 Hansson L, Hedner T, Lund-Johansen P, Kjeldsen S E, Lindholm L H, Syvertsen J O, Lanke J, de Faire U, Dahlöf B, Karlberg B E. for the NORDIL Study Group . Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study.  Lancet. 2000;  356 359-365
• 10 Hansson L, Lindholm L H, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg B E, Wester P O, Björck J E. for the Captopril Prevention Project (CAPPP) study group . Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.  Lancet. 1999;  353 611-616
• 11 Hennersdorf M G, Hafke G J, Steiner S, Dierkes S, Jansen A, Perings C, Strauer B E. Determinanten des paroxysmalen Vorhofflimmerns bei Patienten mit arterieller Hypertonie.  Z Kardiol. 2003;  92 370-376
• 12 Hennersdorf M G, Hafke G J, Steiner S, Dierkes S, Jansen A, Perings C, Strauer B E. Reduktion des paroxysmalen Vorhofflimmerns durch Hypertrophieregression bei arterieller Hypertonie.  Z Kardiol. 2003;  92 I/60 (Supple 1))
• 13 Kannel W B, Abbott R D, Savage D D, McNamara P M. Epidemiologic features of chronic atrial fibrillation: the Framingham study.  N Engl J Med. 1982;  306 1018-1022
• 14 Kannel W B, Wolf P A, Benjamin E J, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.  Am J Cardiol. 1998;  82 2N-9N
• 15 Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky J L, Sebaoun A. for the College of French Cardiologists . Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study.  Circulation. 1999;  99 3028-3035
• 16 Madrid A H, Bueno M G, Rebollo J MG, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, cano J M, Cabeza P, Moro C. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study.  Circulation. 2002;  106 331-336
• 17 Penado S, Cano M, Acha O, Hernandez J L, Riancho J A. Atrial fibrillation as a risk factor for stroke recurrence.  Am J Med. 2003;  114 203-210
• 18 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation . Analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154 1449-1457
• 19 Schmieder R E, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.  JAMA. 1996;  275 1507-1513
• 20 The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators . A comparison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med. 2002;  347 1825-1833
• 21 Van Gelder I, Hagens V E, Bosker H A, Kingma J H, Kamp O, Kingma T, Said S A, Darmanata J I, Timmermans A JM, Tijssen J GP, Crijns H JGM. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med. 2002;  347 1834-1840
• 22 Vaziri S M, Larson M G, Lauer M S, Benjamin E J, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study.  Hypertension. 1995;  25 1155-1160
• 23 Verdecchia P, Reboldi G, Gattobigio R, Bentvoglio M, Borgioni C, Angeli F, Carluccio E, Sardone M G, Porcellati C. Atrial fibrillation in hypertension: predictors and outcome.  Hypertension. 2003;  41 218-223